Stem Cell Therapy for the Treatment of Hip Osteonecrosis: A 30-Year Review of Progress.
Philippe Hernigou, Matthieu Trousselier, François Roubineau...
https://pubmed.ncbi.nlm.nih.gov/26929793/Actively Recruiting
Led by The Cleveland Clinic · Updated on 2026-09-09
100
Participants Needed
1
Research Sites
8 weeks
Total Duration
Researchers are conducting a randomized, single-blinded clinical trial comparing bone marrow aspirate concentrate BMAC injections to triamcinolone injections in patients with hip osteoarthritis. The study aims to evaluate changes in pain and functional ability over 12 months using patient-reported outcome scores and the 6-minute walk test. The trial also seeks to understand how the concentration of stem cells in the bone marrow relates to patient outcomes. Participants will be randomly assigned to receive either a single bone marrow aspirate injection prepared using the Emcyte PureBMC system or a triamcinolone injection with a sham bone needling procedure to keep participants blinded. Bone marrow aspiration involves collecting about 60 cc of marrow from the posterior iliac spine, concentrating it to 8 cc, and injecting 5 cc into the affected hip under ultrasound guidance. The triamcinolone group receives 40 mg of the drug with lidocaine injected into the hip. Both groups undergo injections under ultrasound guidance. During the study, participants will complete baseline assessments including pain scores and blood tests. Follow-up visits will occur at 6 weeks, 3 months, 6 months, and 12 months after injection to assess pain, function, and walking ability. Safety monitoring includes rapid sterility testing of the bone marrow aspirate. Participants are advised to avoid anti-inflammatory medications and ice at the injection site for six weeks and to continue a pain-free home exercise program. The study duration for each participant spans one year from baseline to final follow-up.
CONDITIONS
Bone Marrow Aspirate Concentrate Versus Triamcinolone Injection For Hip Osteoarthritis
L
LEONARDO P OLIVEIRA, MD
Z
Zoe Healy, MS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The Cleveland Clinic
Lead Sponsor
Lisa Dean Moseley Foundation
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Bone Marrow Aspirate Concentrate (Aspire Needle + Emcyte PureBMC) | Triamcinolone Injection |
|---|---|---|
| What it is | A single intra-articular injection of the participant's own concentrated bone marrow aspirate into the hip joint, prepared using the Aspire Needle for extraction and Emcyte PureBMC for concentration. | A single intra-articular injection of triamcinolone (40 mg) with lidocaine into the hip joint, serving as an active comparator. |
| Role in trial | Investigational treatment being tested for pain and functional improvement in hip osteoarthritis. | Active comparator arm representing guideline-endorsed standard treatment for hip osteoarthritis. |
| Primary use | Evaluated as a potential regenerative treatment to reduce pain and improve function in adults with hip osteoarthritis. | Used to relieve symptoms of pain and inflammation in people with hip osteoarthritis. |
| How it is given or performed | Bone marrow is extracted, concentrated using a closed system, and injected into the affected hip joint in a single procedure. | A single injection of triamcinolone (with lidocaine) is delivered into the hip joint. |
| Published clinical evidence status | Ongoing clinical investigation. No large randomized trials in hip osteoarthritis; available evidence consists mainly of small studies and systematic reviews indicating potential benefit for pain relief, but definitive conclusions await larger high-quality trials. | Supported by clinical guidelines and moderate-quality trial evidence for symptom relief in hip osteoarthritis. Steroid injections are effective for short-term pain reduction, though benefits may diminish over time. |
| Important limitations | Uncertainty because of limited high-quality trial evidence for hip osteoarthritis, potential variability in bone marrow cell composition, and lack of established long-term efficacy or safety. | Symptom relief from steroid injection is generally short-term; repeated injections may not improve long-term joint outcomes. Potential for site-related or systemic steroid effects exists. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single visit with monitoring for 15 minutes post-injection
Participants receive either a bone marrow aspirate concentrate injection or a triamcinolone injection into the affected hip under ultrasound guidance. The triamcinolone group undergoes a sham bone needling procedure to keep participants blinded.
1 visit (in-person)
Duration - 12 months
Participants return for follow-up visits at 6 weeks, 3 months, 6 months, and 12 months to complete pain and function assessments, including patient-reported outcomes and the 6-minute walk test.
4 visits (in-person)
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Philippe Hernigou, Matthieu Trousselier, François Roubineau...
https://pubmed.ncbi.nlm.nih.gov/26929793/A Skwara, R Ponelis, C O Tibesku...
https://pubmed.ncbi.nlm.nih.gov/19380288/RobRoy L Martin, Marc J Philippon
https://pubmed.ncbi.nlm.nih.gov/18514111/Gi Beom Kim, Min-Soo Seo, Wook Tae Park...
https://pubmed.ncbi.nlm.nih.gov/32370163/Robert H Quinn, Jayson Murray, Ryan Pezold...
https://pubmed.ncbi.nlm.nih.gov/30134309/Mark C Walters
https://pubmed.ncbi.nlm.nih.gov/25767957/Christopher J Centeno, Hasan Al-Sayegh, Michael D Freeman...
https://pubmed.ncbi.nlm.nih.gov/27026621/Jonathon Charlesworth, Jane Fitzpatrick, Nirmala Kanthi Panagodage Perera...
https://pubmed.ncbi.nlm.nih.gov/30961569/Nicolas S Piuzzi, Venkata P Mantripragada, Alan Sumski...
https://pubmed.ncbi.nlm.nih.gov/30461435/Mayo F Friedlis, Christopher J Centeno
https://pubmed.ncbi.nlm.nih.gov/27788908/The Cleveland Clinic
Lead Sponsor
Lisa Dean Moseley Foundation
Collaborating Sponsor